Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Walvax PCV13-TT vs Pfizer PCV13 in Indonesian Infants
NCT05934890Phase 3Active, not recruiting
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of WALVAX PCV13 in invasive pneumococcal disease (IPD), sponsored by Walvax Biotechnology Co., Ltd.. Started Nov 2023; status: active, not recruiting.
02
Drugs
WALVAX PCV13
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on NCT05934890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934890.